References
- Borsetti A, Scarpa F, Maruotti A, et al. The unresolved question on COVID‐19 virus origin: the three cards game? J Med Virol. 2022;94(4):1257–1260. doi: 10.1002/jmv.27519
- Scarpa F, Ciccozzi M. On the SARS-CoV-2 BA.2.86 lineage: a mutation point of view. J Med Virol. 2023;95:e29079. doi: 10.1002/jmv.29079
- World Health Organization. WHO tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants.
- World Health Organization. WHO tracking SARS-CoV-2 variants. BA.2.86 initial risk evaluation. [cited 2023 November 21]. Available online: https://www.who.int/docs/default-source/coronaviruse/21112023_ba.2.86_ire.pdf?sfvrsn=8876def1_3.
- GISAID Portal EpiCoV Search. https://www.epicov.org/epi3/frontend#227d24.
- Wang Q, Guo Y, Liu L, et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023;624(7992):639–644. doi: 10.1038/s41586-023-06750-w
- Liu Y, Liu J, Johnson BA, et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 2022;39(7):110829. doi: 10.1016/j.celrep.2022.110829
- Saito A, Irie T, Suzuki R, et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 delta P681R mutation. Nature. 2022;602(7896):300–306. doi: 10.1038/s41586-021-04266-9
- Focosi D, Maggi F. Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Vir. 2021;31(6):e2231. doi: 10.1002/rmv.2231
- Yang WT, Huang WH, Liao TL, et al. SARS-CoV-2 E484K mutation narrative review: epidemiology, immune escape, clinical implications, and future considerations. Infect Drug Resist. 2022;15:373–385. doi: 10.2147/IDR.S344099
- GitHub depository. https://github.com/nextstrain/ncov.
- World Health Organization. Weekly Epidemiological Update on COVID-19 [cited 2023 November 24]. Available from: https://www.who.int/publications/m/item/covid-19-epidemiological-update—24-november-2023.